Third Harmonic Bio
Cambridge
About Third Harmonic Bio
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with allergic diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $158.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2025)
- Ticker: nasdaq:THRD
- Website: thirdharmonicbio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/third-harmonic-bio-60752 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.